Keen Vision Acquisition Corporation
Description
Keen Vision Acquisition Corporation does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, and related business combination with one or more businesses or entities. It also intends to focus on businesses in the biotechnology, consumer goods, and agriculture sectors. The company was incorporated in 2021 and is based in Summit, New Jersey.
About
CEO
Mr. Ka Chun Wong
Employees
0
Instrument type
Common Stock
Sector
Financial Services
Industry
Shell Companies
MIC code
XNMS
Address
37 Greenbriar Drive, Summit, NJ 07901, United States
×
![Enlarged Chart]()
Oscillators
No data available
Summary
No data available
Moving Averages
No data available
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Nov 3, 2025 | — | — | — | — |
| Jul 23, 2025 | — | — | — | — |
| May 13, 2025 | — | — | — | — |
| Mar 25, 2025 | — | — | — | — |
Earnings estimate
| Number of analysts | — | — | — | — |
|---|---|---|---|---|
| Average estimate | — | — | — | — |
| Low estimate | — | — | — | — |
| High estimate | — | — | — | — |
| Last year EPS | — | — | — | — |
[stock_revenue_estimate]
Growth estimates
Current qtr
—
Next qtr.
—
Current year
—
Next year
—
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | |
|---|---|
| Fiscal date | 2023-12-31 |
| Total reported revenue | — |
| Cost of revenue | — |
| Gross profit | — |
| Operating expense | |
| Research & development | — |
| Selling general and admin | — |
| Other operating expenses | 478,676 |
| Operating income | -478,676 |
| Non operating interest income | |
| Income | 1.93M |
| Expense | — |
| Other income expense | 2 |
| Pretax income | 1.45M |
| Tax provision | — |
| Net income | 1.45M |
| Basic EPS | 0.25 |
| Diluted EPS | 0.25 |
| Basic average shares | 4.03M |
| Diluted average shares | 4.03M |
| EBITDA | -478,678 |
| Net income from continuing op. | 1.45M |
| Minority interests | — |
| Preferred stock dividends | — |
Balance sheet
| 2023 | 2022 | 2021 | |
|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 155.69M | 194,807 | 139,424 |
| Current assets | |||
| Cash | 631,753 | 77,709 | 24,924 |
| Cash equivalents | — | — | — |
| Cash and cash equivalents | 631,753 | 77,709 | 24,924 |
| Other short term investments | — | — | — |
| Accounts receivable | — | — | — |
| Other receivables | — | — | — |
| Inventory | — | — | — |
| Prepaid assets | 233,862 | 2,598 | — |
| Restricted cash | — | — | — |
| Assets held for sale | — | — | — |
| Hedging assets | — | — | — |
| Other current assets | — | — | — |
| Non current assets | |||
| Properties | — | — | — |
| Land and improvements | — | — | — |
| Machinery furniture equipment | — | — | — |
| Construction in progress | — | — | — |
| Leases | — | — | — |
| Accumulated depreciation | — | — | — |
| Goodwill | — | — | — |
| Investment properties | — | — | — |
| Financial assets | — | — | — |
| Intangible assets | — | — | — |
| Investments and advances | — | — | — |
| Other non current assets | 154.82M | 114,500 | 114,500 |
| Total liabilities | 3.00M | 173,573 | 117,497 |
| Current liabilities | |||
| Accounts payable | — | — | — |
| Accrued expenses | 4,000 | — | — |
| Short term debt | — | 173,573 | 117,497 |
| Deferred revenue | — | — | — |
| Tax payable | — | — | — |
| Pensions | — | — | — |
| Other current liabilities | — | — | — |
| Non current liabilities | |||
| Long term debt | — | — | — |
| Provision for risks and charges | — | — | — |
| Deferred liabilities | — | — | — |
| Derivative product liabilities | — | — | — |
| Other non current liabilities | — | — | — |
| Shareholders equity | |||
| Common stock | 154.82M | 374 | 374 |
| Retained earnings | -3.66M | -3,766 | -3,073 |
| Other shareholders equity | 1.52M | — | — |
| Total shareholders equity | 152.68M | 21,234 | 21,927 |
| Additional paid in capital | — | 24,626 | 24,626 |
| Treasury stock | — | — | — |
| Minority interest | — | — | — |
Cash flow statement
| 2023 | |
|---|---|
| Operating Activities | |
| Net Income | 1.45M |
| Depreciation | — |
| Deferred Taxes | — |
| Stock-Based Compensation | — |
| Other Non-Cash Items | -1.93M |
| Accounts Receivable | — |
| Accounts Payable | — |
| Other Assets & Liabilities | — |
| Operating Cash Flow | -478,637 |
| Investing Activities | |
| Capital Expenditures | — |
| Net Intangibles | — |
| Net Acquisitions | — |
| Purchase of Investments | — |
| Sale of Investments | — |
| Investing Cash Flow | -151.37M |
| Financing Activities | |
| Long-Term Debt Issuance | — |
| Long-Term Debt Payments | -367,500 |
| Other Financing Charges | -3.61M |
| Financing Cash Flow | 152.26M |
| Other Cash Details | |
| End Cash Position | 631,753 |
| Income Tax Paid | — |
| Interest Paid | — |
| Free Cash Flow | -705,903 |
Top Institutional Holders
| Holder | Date Reported | Shares | Value | % Held |
|---|---|---|---|---|
| Investment Managers Ser Tr II-First Trust Merger Arbitrage Fd | Sep 30, 2024 | 1,396,579 | 15.52M | 12.91% |
| Merger Fund, The | Sep 30, 2024 | 622,800 | 6.92M | 5.76% |
| CrossingBridge Pre-Merger SPAC ETF | Sep 30, 2024 | 255,847 | 2.84M | 2.36% |
| Calamos Market Neutral Income Fund | Oct 31, 2024 | 100,000 | 1.11M | 0.92% |
| Investment Managers Ser Tr II-First Trust Multi-Strategy Fd | Sep 30, 2024 | 30,250 | 336,077 | 0.28% |
| JNL Series Trust-JNL/Multi Manager Alternative Fund | Sep 30, 2024 | 26,898 | 298,836 | 0.25% |
| Listed Funds Tr-RiverNorth Enhanced Pre-Merger SPAC ETF | Sep 30, 2024 | 10,401 | 115,555 | 0.10% |
| Fidelity NASDAQ Composite Index Fund | Nov 30, 2024 | 10,534 | 117,032 | 0.10% |
| WCM Alternatives Credit Event Fund | Sep 30, 2024 | 10,544 | 117,143 | 0.10% |
| Merger Fund Vl, The | Sep 30, 2024 | 8,495 | 94,379 | 0.08% |
Article
Medera's Novoheart Expands Human Cardiac Research with CTScreen™ Installation at University Medical Center, Utrecht
Cutting-Edge Cardiac Research: Novoheart's CTScreen™ system has been installed at UMC Utrecht, equipping Regenerative Medicine Center with advanced high-throughput tools to accelerate human cardiac disease modeling and therapeutic screening, including both drug candidates and gene editing approaches Driving Innovation: This installation paves the way for future co-development projects with UMC Utrecht, advancing human-based research and cardiac regenerative technologies BOSTON and UTRECHT, Netherlands, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat or currently incurable diseases with significant unmet needs, and Novoheart, its wholly owned pre-clinical subsidiary pioneering human-based cardiac tissue engineering for disease modelling and drug screening, are pleased to announce the installation of their state-of-the-art CTScreen™ platform at the University Medical Center Utrecht (UMC Utrecht). This milestone equips the Regenerative Medicine Center Utrecht with a leading-edge system to model human cardiac diseases, develop therapies, and transform preclinical cardiac research.
Feb 10, 2025
Article
Medera, Inc. to Participate in Two Upcoming Investor Conferences
SUMMIT, N.J. and BOSTON, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Medera, Inc., (“Medera”), a clinical-stage biotechnology company, announced today that the management team will participate in the two upcoming investor conferences in February 2025 as follows:
Feb 7, 2025
Article
Medera Announces Publication of Study Utilizing Machine Learning to Enhance Next-Generation Drug Screening with Human mini-Heart Technology
Traditional methods for evaluating therapeutic efficacy and cardiotoxicity often lead to high failure rates during clinical trials, resulting in significant development costs Human-specific diseases cannot be accurately modeled by animals, leading to limited medical options or advancements This new study leverages the capabilities of artificial intelligence (AI) and machine learning (ML) to address the challenge of achieving automated and comprehensive "smart" drug screening using Medera's mini-Heart technology platform Innovative AI/ML-based model combines data from multiple human mini-Heart screening assays and takes advantage of the complementary strengths to achieve superior next-generation drug classification capabilities The unique combination of AI/ML and human mini-Hearts can accelerate drug discovery, clinical translation and precision medicine by improving screening efficiency, reducing costs, enhancing safety and creating new opportunities for patient benefits SUMMIT, N.J. and BOSTON, Mass.
Oct 31, 2024
